Quantbot Technologies LP Makes New Investment in Lantheus Holdings, Inc. $LNTH

Key Points

• Quantbot Technologies LP opened a new position in Lantheus, buying 36,014 shares worth about $1.85 million and representing roughly 0.05% of the company at quarter-end.
• Lantheus beat estimates with Q earnings of $1.67 vs. $1.17 expected and revenue of $406.8M vs. $367.0M, set FY2026 EPS guidance of $5.00–$5.25, and now has an average analyst target of $82.17 with a consensus rating of "Moderate Buy" (7 Buys, 3 Holds).
• Institutional investors and hedge funds own about 99.06% of the stock, which trades near $77.84 with a market cap around $5.03 billion and a P/E of 23.1.

Quantbot Technologies LP bought a new position in shares of Lantheus Holdings, Inc. (NASDAQ:LNTH - Free Report) in the 3rd quarter, according to its most recent 13F filing with the SEC. The fund bought 36,014 shares of the medical equipment provider's stock, valued at approximately $1,847,000. Quantbot Technologies LP owned 0.05% of Lantheus at the end of the most recent quarter.

A number of other hedge funds have also modified their holdings of the company. Hantz Financial Services Inc. grew its holdings in Lantheus by 412.5% during the third quarter. Hantz Financial Services Inc. now owns 492 shares of the medical equipment provider's stock valued at $25,000 after purchasing an additional 396 shares during the period. Elevation Point Wealth Partners LLC bought a new position in shares of Lantheus during the second quarter worth $26,000. First Horizon Corp acquired a new position in shares of Lantheus in the 3rd quarter valued at $26,000. Osterweis Capital Management Inc. bought a new stake in shares of Lantheus in the 2nd quarter valued at $36,000. Finally, Pilgrim Partners Asia Pte Ltd bought a new stake in shares of Lantheus in the 3rd quarter valued at $59,000. 99.06% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several research analysts have weighed in on the company. Mizuho lifted their target price on Lantheus from $72.00 to $85.00 and gave the stock an "outperform" rating in a report on Friday, February 27th. Truist Financial lifted their price objective on Lantheus from $82.00 to $89.00 and gave the company a "buy" rating in a report on Friday, February 27th. Citigroup restated an "outperform" rating on shares of Lantheus in a report on Tuesday, February 24th. JonesTrading cut shares of Lantheus from a "buy" rating to a "hold" rating in a report on Friday, February 27th. Finally, Citizens Jmp increased their price objective on shares of Lantheus from $73.00 to $78.00 and gave the stock a "market outperform" rating in a research report on Tuesday, February 24th. Seven analysts have rated the stock with a Buy rating and three have given a Hold rating to the company. Based on data from MarketBeat, the company currently has an average rating of "Moderate Buy" and an average target price of $82.17.

Lantheus Trading Down 1.3%

NASDAQ LNTH opened at $77.84 on Thursday. Lantheus Holdings, Inc. has a 52 week low of $47.25 and a 52 week high of $111.29. The company has a debt-to-equity ratio of 0.52, a quick ratio of 2.51 and a current ratio of 2.70. The stock's 50 day moving average price is $68.79 and its two-hundred day moving average price is $60.68. The stock has a market capitalization of $5.03 billion, a price-to-earnings ratio of 23.10 and a beta of -0.11.

Lantheus (NASDAQ:LNTH - Get Free Report) last issued its quarterly earnings results on Thursday, February 26th. The medical equipment provider reported $1.67 earnings per share for the quarter, topping the consensus estimate of $1.17 by $0.50. The company had revenue of $406.79 million during the quarter, compared to analysts' expectations of $367.03 million. Lantheus had a net margin of 15.15% and a return on equity of 30.77%. The business's quarterly revenue was up 4.0% on a year-over-year basis. During the same period last year, the business earned $1.59 EPS. Lantheus has set its FY 2026 guidance at 5.000-5.250 EPS. As a group, analysts anticipate that Lantheus Holdings, Inc. will post 6.01 earnings per share for the current fiscal year.

Lantheus Company Profile

Lantheus Holdings, Inc is a global life sciences company specializing in the development, manufacturing and commercialization of diagnostic imaging agents and radiopharmaceuticals. Headquartered in North Billerica, Massachusetts, Lantheus focuses on products that enhance the detection and management of cardiovascular and oncologic diseases. The company's portfolio spans ultrasound-enhancing agents, molecular imaging tracers for positron emission tomography (PET), and emerging theranostic platforms designed to pair diagnostic and therapeutic applications.

The diagnostic imaging segment includes ultrasound contrast agents such as DEFINITY® (perflutren lipid microsphere) and Sonazoid® (perflubutane), which improve the visualization of cardiac structures and blood flow.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.